NCT01457508View on ClinicalTrials.gov

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately

PHASE3CompletedINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

January 31, 1999

Primary Completion Date

March 31, 2000

Study Completion Date

March 31, 2000

Conditions
Hepatitis BDiphtheriaHaemophilus Influenzae Type b (Hib)PoliomyelitisPertussisTetanus
Interventions
BIOLOGICAL

DTPa-HBV-IPV/Hib (Infanrix hexa™)

Three doses administered intramuscularly

BIOLOGICAL

DTPa-HBV-IPV (Infanrix penta™)

Three doses administered intramuscularly

BIOLOGICAL

Hib (Hiberix™)

Three doses administered intramuscularly

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01457508 - Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately | Biotech Hunter | Biotech Hunter